

Ken Fujioka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9115720/publications.pdf>

Version: 2024-02-01

37
papers

4,216
citations

257357

24
h-index

345118

36
g-index

37
all docs

37
docs citations

37
times ranked

4269
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of pharmacologic weight loss in patients with cirrhosis. <i>Obesity Science and Practice</i> , 2021, 7, 159-167.	1.0	3
2	Barriers and Solutions for Prescribing Obesity Pharmacotherapy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 303-314.	1.2	13
3	Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes. <i>International Journal of Obesity</i> , 2020, 44, 990-998.	1.6	5
4	Effect of lorcaserin on weight reduction in persons with obstructive sleep apnea (OSA): a combined subgroup analysis from three randomized, controlled clinical trials. <i>Obesity Science and Practice</i> , 2019, 5, 238-245.	1.0	4
5	A call to action to inform patient-centered approaches to obesity management: Development of a disease-illness model. <i>Clinical Obesity</i> , 2019, 9, e12309.	1.1	38
6	Effect of lorcaserin in different age groups: a post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM-DM studies. <i>Obesity Science and Practice</i> , 2019, 5, 120-129.	1.0	4
7	Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 1419-1422.	1.3	12
8	Obesity Pharmacotherapy in Patients With Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2017, 30, 250-257.	0.4	29
9	Update on bariatric surgical procedures and an introduction to the implantable weight loss device: the Maestro Rechargeable System. <i>Medical Devices: Evidence and Research</i> , 2016, Volume 9, 291-299.	0.4	8
10	Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 558-570.	2.2	134
11	What weight loss treatment options do geriatric patients with overweight and obesity want to consider?. <i>Obesity Science and Practice</i> , 2016, 2, 477-482.	1.0	4
12	Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes. <i>Obesity</i> , 2016, 24, 2269-2277.	1.5	44
13	Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. <i>Obesity</i> , 2016, 24, 2278-2288.	1.5	88
14	The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. <i>International Journal of Obesity</i> , 2016, 40, 1369-1375.	1.6	52
15	Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e142.	1.3	155
16	Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 164-174.	1.3	8
17	Current and emerging medications for overweight or obesity in people with comorbidities. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1021-1032.	2.2	58
18	A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. <i>New England Journal of Medicine</i> , 2015, 373, 11-22.	13.9	1,492

#	ARTICLE	IF	CITATIONS
19	Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 4022-4029.	4.3	354
20	Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 863-866.	2.2	44
21	Nutrition and Metabolic Complications After Bariatric Surgery and Their Treatment. <i>Journal of Parenteral and Enteral Nutrition</i> , 2011, 35, 52S-9S.	1.3	38
22	Vomiting From Multivitamins: A Potential Drug Interaction. <i>American Journal of Therapeutics</i> , 2011, 18, 453-457.	0.5	2
23	Office-based Management of Obesity. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 466-471.	1.9	1
24	Do Gastric Bypass Patient Characteristics, Behavior, and Health Differ Depending upon how Successful Weight Loss is Defined?. <i>Obesity Surgery</i> , 2010, 20, 1385-1392.	1.1	30
25	Benefits of moderate weight loss in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 186-194.	2.2	51
26	Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4898-4906.	1.8	151
27	Pre- and Postsurgery Behavioral Compliance, Patient Health, and Postbariatric Surgical Weight Loss. <i>Obesity</i> , 2009, 17, 996-1002.	1.5	151
28	Naltrexone for the treatment of obesity: review and update. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1841-1845.	0.9	40
29	American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical Guidelines for Clinical Practice for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient. <i>Endocrine Practice</i> , 2008, 14, 1-83.	1.1	154
30	Weight Loss Clinics. , 2008, , 593-605.		1
31	Pharmacologic Treatment Options for Obesity: Current and Potential Medications. <i>Nutrition in Clinical Practice</i> , 2007, 22, 50-54.	1.1	12
32	The Effects of Grapefruit on Weight and Insulin Resistance: Relationship to the Metabolic Syndrome. <i>Journal of Medicinal Food</i> , 2006, 9, 49-54.	0.8	104
33	Follow-up of Nutritional and Metabolic Problems After Bariatric Surgery. <i>Diabetes Care</i> , 2005, 28, 481-484.	4.3	220
34	Management of Obesity as a Chronic Disease: Nonpharmacologic, Pharmacologic, and Surgical Options. <i>Obesity</i> , 2002, 10, 116S-123S.	4.0	102
35	Bupropion SR Enhances Weight Loss: A 48-Week Double-Blind, Placebo-Controlled Trial. <i>Obesity</i> , 2002, 10, 633-641.	4.0	268
36	Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 175-187.	2.2	230

#	ARTICLE	IF	CITATIONS
37	Use of relative weight and body mass index for the determination of adiposity. Journal of Clinical Epidemiology, 1991, 44, 545-550.	2.4	112